A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study was published in the 30 September 2011 issue of the Journal “Cell” [I.F: 33.116] by Prof Daley GQ, Zhu H, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based Regenerative therapy for DM: Angiopoietin-like protein 2 (Angptl2) promotes insulin resistance via down regulation of reprogramming protein Lin28
Significance: Prof. Daley GQ and his team members had earlier shown that loss of Lin28 promotes insulin resistance and glucose intolerance. The study presented here suggests, for the first time, that Angptl2, by increasing the expression of its target gene, it may decrease the expression of RNA-binding protein Lin-28, and thereby promote insulin resistance. Thus, pharmacological formulations encompassing “Angptl2 inhibitors“ may be used to treat DM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How Angptl2 increases the expression of Lin28
To cite: Boominathan, MiRNA-based Regenerative therapy for DM: Angiopoietin-like protein 2 (Angptl2) promotes insulin resistance via down regulation of reprogramming protein Lin28, 3/April/2015, 06.35 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
